Iovance Biotherapeutics (DE:2LB)
NASDAQ:2LB
2LB Stock Chart & Stats
€3.20
-€0.05(-0.70%)
At close: 4:00 PM EST
€3.20
-€0.05(-0.70%)
Day’s Range― - ―
52-Week Range€1.43 - €4.74
Previous CloseN/A
Volume0.00
Average Volume (3M)1.46K
Market Cap
€1.64B
Enterprise Value€1.32B
Total Cash (Recent Filing)€313.44M
Total Debt (Recent Filing)€46.78M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume3,709
30 Day Avg. Volume1,456
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.50Price Target Upside165.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€309.29M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line acceleration and strong Amtagvi demand imply expanding market adoption and improving commercial traction. Rising physician awareness and ATC network expansion support durable per-patient volume growth and a firmer revenue base over the next 2–6 months.
In-house Manufacturing CapacityOwning a modular internal manufacturing facility reduces supply risk, improves quality control and supports scalable throughput. This structural capability enhances margin sustainability and lowers reliance on third parties as commercial volumes increase.
Improved Cost Discipline & RunwayConsecutive R&D cuts and a stated multi-year runway provide operational breathing room to execute commercialization and registrational plans without immediate financing. Better cost control supports margin improvement as one-time headwinds abate.
Bears Say
Sustained Cash BurnLarge negative operating and free cash flow indicate the business is consuming significant liquidity; absent persistent margin improvement or external funding, this reduces financial flexibility, increases financing reliance, and heightens execution risk over the medium term.
Persistent Losses & Negative ROEDeep, ongoing net losses and sharply negative ROE show shareholder capital is being eroded. Until commercialization scales enough to offset operating spend, sustained capital consumption will constrain reinvestment and reduce tolerance for missed milestones.
Regulatory & Execution RelianceKey revenue and pipeline milestones depend on timely approvals and trial enrollment; delays or heterogeneous standards of care can postpone launches or shrink addressable markets. Combined with ongoing ATM use, this elevates outcome and dilution risk over the next several quarters.
Iovance Biotherapeutics News
2LB FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was €1.43 and its highest was €4.74 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is €1.64B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -€0.163 earnings per share for the quarter, missing the consensus estimate of -€0.132 by -€0.031.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.11.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -€0.163 in its last earnings report, missing expectations of -€0.132. Following the earnings report the stock price went up 1.471%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in DE:2LB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.50 (165.76% Upside)
€8.50 (165.76% Upside)
Blogger Sentiment
Bullish
DE:2LB Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.00%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
2LB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.View all DE:2LB earnings summaries2LB Stock 12 Month Forecast
Average Price Target
€8.50
▲(165.76% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---